CompletedPhase 4

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

United States200 participantsStarted 2006-09

Plain-language summary

The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.

Who can participate

Age range6 Months – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children between the ages of 6 months and 18 years of age (inclusive) * Suspected purulent staphylococcal skin or soft tissue infection * No hospitalization within the previous 14 days * Must have reliable means of follow-up contact (e.g. working phone) * Outpatient management in the judgement of treating physician Exclusion Criteria: * Hospitalization on initial visit * Voluntary withdrawal by the treating physician in order to dictate the antibiotic being used * Patients with a history of hypersensitivity to or intolerance of cephalexin (or other beta lactams) or clindamycin. * Patients with altered immunity (inherited or acquired) * Patients with skin infections related to surgical wounds or hardware. * Patients currently on antibiotic therapy

What they're measuring

Clinical Improvement at the 48-72 Hour Clinical Follow-up

Timeframe: 48-72 hour clinical follow-up

Trial details

NCT IDNCT00352612

SponsorAaron Chen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-05

Results submitted2012-04-10

View on ClinicalTrials.gov More Staphylococcal Infection trials